Michel Vounatsos, Biogen CEO (via YouTube)

FDA OKs ad­u­canum­ab for Alzheimer's, turn­ing con­tro­ver­sial Bio­gen drug in­to a megablock­buster

The FDA has ap­proved the Bio­gen drug ad­u­canum­ab for Alzheimer’s, a stun­ning de­ci­sion that caps near­ly two years of con­tro­ver­sy and hands the large biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.